News articles about Axsome Therapeutics (NASDAQ:AXSM) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Axsome Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.4439792002757 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
AXSM has been the subject of several recent research reports. BTIG Research initiated coverage on shares of Axsome Therapeutics in a research report on Friday, May 19th. They issued a “buy” rating and a $14.00 price target for the company. Zacks Investment Research upgraded shares of Axsome Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research note on Wednesday, May 24th. Aegis reiterated a “buy” rating and set a $20.00 price target on shares of Axsome Therapeutics in a research note on Thursday, May 25th. ValuEngine upgraded shares of Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 21st. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $31.00 price target (up from $28.00) on shares of Axsome Therapeutics in a research note on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Axsome Therapeutics presently has an average rating of “Buy” and an average target price of $17.08.
Axsome Therapeutics (AXSM) traded up 3.51% during trading on Tuesday, hitting $5.90. 74,366 shares of the stock were exchanged. Axsome Therapeutics has a 12-month low of $3.53 and a 12-month high of $9.11. The stock’s 50-day moving average price is $5.41 and its 200-day moving average price is $4.57. The firm’s market cap is $139.27 million.
Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, May 9th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by $0.01. On average, equities analysts expect that Axsome Therapeutics will post ($1.43) EPS for the current year.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.